RT Journal Article
SR Electronic
T1 Clinical Observation of FMD Regimen: Fludarabine, Mitoxantrone, Dexamethasone, in Treatment of Non-Hodgkin's Lymphoma
JF Chinese Journal of Clinical Oncology
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 433
OP 436
DO 10.1007/s11805-008-0433-4
VO 5
IS 6
A1 Shuqing Lü
A1 Jianmin Wang
A1 Xianmin Song
A1 Li Chen
A1 Weiping Zhang
A1 Jun Hou
A1 Xiaoqian Xu
A1 Chongmei Huang
A1 Jianmin Yang
YR 2008
UL http://www.cancerbiomed.org/content/5/6/433.abstract
AB OBJECTIVE To evaluate the clinical effectivity and toxicity of the regimen FMD (fludarabine, mitoxantrone, dexamethasone) in patients with non-Hodgkin’s lymphoma.METHODS Thirty-two patients, twenty-four of whom had indolent B-cell lymphoma, 6 peripheral T-cell lymphoma, two diffuse large B-cell lymphoma, received FMD. Treatment comprised: fludarabine 25~30 mg/m2 days 1~3, mitoxantrone 8~10 mg/m2 day 1, and dexamethasone 20~30 mg/m2 days 1~5. At the same time, patients received prophylaxis against conditional infection with trimethoprim-sulfamethoxazole, fluconazole, acyclovir and immunoglobulin.RESULTS Of the thirty-two patients treated, the complete response (CR) rate, partial response (PR) rate and overall response (OR) rate were 56.3%, 21.9% and 78.2% respectively. The CR and OR rate of 24 patients with indolent B-cell lymphoma were 66.7% and 88.3% respectively. Two of six patients with peripheral T-cell lymphoma were of complete response type and one was of partial response type. One of two patients with diffuse large B-cell lymphoma was partial response. The dominating toxicity was myelotoxicity and immunotoxicity. There was no treatment associated death in all patients treated with FMD. Grade 3~4 neutropenia occurred in 43.8% patients, 12.5% patients had infections and 9.3% developed grade 3~4 thrombocytopenia. At a median follow-up of 24 (5~54) months, the 2-year overall-survival rate and progression-free survival rate were (87.5 ± 1.4)% and (83.3 ± 1.6)% respectively. The 2-year OS and PFS rates of the indolent group were (93.75 ± 6.25)% and (87.5 ± 8.54)%.CONCLUSION FMD regimen was highly effective with low toxicity in the treatment of non-Hodgkin’s lymphoma, especially in indolent B-cell lymphoma. It also helps to improve the prognosis even in some aggressive lymphoma, such as peripheral T cell lymphoma.